Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orticumab in post-MI patients with elevated coronary inflammation
NCT06927739Phase 2Recruiting
- Sponsor
- Abcentra
- Start
- Aug 2025
- Primary completion
- Feb 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of orticumab in coronary artery disease (CAD) (4 arms), sponsored by Abcentra. Primary endpoint: Fat Attenuation Index at 24 weeks. Started Aug 2025; status: recruiting.
02
Drugs
orticumab
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06927739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06927739.